INTRODUCTION
Type 2 diabetes mellitus is characterized by peripheral insulin resistance and low-grade systemic inflammation. Plasma levels of inflammation markers C-reactive protein (CRP), and IL-6 have been shown to predate the onset of Type 2 diabetes mellitus in women [1] , suggesting that low-grade systemic inflammation plays a significant role in the onset of type 2 diabetes mellitus. In this regard, light-to-moderate alcohol intake has been associated with reduced inflammation [2] as well as lower insulin levels and improved glycaemic control [3] .
Further, a meta-analysis of 706,716 individuals showed that light -moderate alcohol consumption associated with a reduced risk of developing Type 2 diabetes mellitus [4] and the Health Professionals Follow-up Study showed moderate alcohol intake associated with reduced inflammatory markers such as fibrinogen, soluble tumour necrosis factor receptor-2, and soluble vascular adhesion molecule-1 in Type 2 diabetes mellitus [5] . These findings suggest that the anti-inflammatory effects of moderate alcohol consumption may provide protection against development of Type 2 diabetes mellitus.
Inflammation resolution is recognised as an important process that is driven by specialised pro-resolving mediators of inflammation (SPMs) and has the potential to moderate chronic inflammation [6, 7] . The SPM's include lipoxins from arachidonic acid (AA) and resolvins, protectins and maresins derived from the omega-3 fatty acids, eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) [6] . SPM synthesis from EPA is via metabolism by cyclooxygenase-2 (COX-2) or cytochrome P450 (CYP450) to 18-hydroxyeicosapentaenoic acid (18-HEPE) with further metabolism by 5-lipoxygenase (5-LOX) and 15-lipoxygenase (15-LOX) to form the E-series resolvins (RvE1-RvE3). SPM synthesis from DHA occurs by metabolism by COX-2/15-LOX to 17-hydroxydocosahexaenoic acid (17-HDHA) that is further metabolised to Protectin D1 (PD1), and via 5-LOX to the D-series resolvins (such as RvD1, 17R-RvD1, RvD2 and RvD5). DHA metabolism by 12-lipoxygenase (12-LOX) leads to another group of SPM, the Maresins (MaR-1) and 14-hydroxydocosahexaenoic acid (14-HDHA) [6, 7] . SPMs halt neutrophil infiltration and enhance macrophage uptake of apoptotic cells and debris, promoting a return to homeostasis after an inflammatory event [6, 7] .
Alcohol has the potential to affect synthesis of SPMs by altering the availability of fatty acid substrates, [8] and the activity of, COX-2 [9] and 5-lipoxygenase [10] that are key enzymes involved in SPM synthesis and is also known to affect cytochrome P450 enzymes [11] and CYP450 metabolism to eicosanoids [12] [13] [14] .
In a controlled trial in persons with Type 2 diabetes mellitus, that compared red wine with dealcoholized red wine (DRW) and water, we showed that red wine increased awake systolic and diastolic blood pressure and heart rate relative to water and DRW, without affecting glycemic control [15] . In a trial of similar design in healthy men we showed that consumption of alcohol as red wine increased plasma SPM levels [13] . The finding that alcohol stimulated plasma SPM in healthy volunteers suggested that alcohol may also affect SPM in diabetic patients who are known to have low grade systemic inflammation.
In this report we aimed to examine the effects of red wine on plasma SPM in plasma samples collected from the same randomised controlled trial of red wine in patients with Type 2 diabetes mellitus [15] . In addition, we compared plasma SPM levels in patients with Type 2 diabetes mellitus with those of healthy volunteers.
2.
PATIENTS AND METHODS symptomatic heart disease, angina pectoris, history of myocardial infarction or stroke, peripheral vascular disease, major surgery 3 months or less, BP > 170/ 100 mmHg, liver or renal disease (plasma creatinine >120 mmol/l), haemoglobin A1c (HbA1c) more than 8.5%
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(>69 mmol/mol), and current smokers or ex-smokers (<2 years). Antihypertensive or lipidlowering medication usage were not exclusion criteria.
Study design
After a 4-week run-in period of usual alcohol intake, 24 participants (19 men and 5 women)
with Type 2 diabetes mellitus were randomised to a 12 week three-period cross-over study of Latin square design. The three study periods each of 4 weeks were, red wine with women drinking 230 ml/day (~24 g alcohol/day) and men drinking 300 ml/day (~31 g alcohol/day), 
Measurements
Measurements were at the end of the 4-week run-in period and at the end of each 4-week study period following an overnight fast. Compliance with alcohol intake during the study was recorded using 7-day retrospective diaries completed at weekly visits to the Clinical Trials Unit. Plasma -glutamyl transpeptidase (-GT) was measured as a biomarker of change in alcohol intake during the 4 week run-in period and at the end of each 4 week study period.
Twenty four-hour urinary 4-O-methylgallic acid a biomarker of polyphenol content of red wine was determined at the same time points by gas chromatography-mass spectrometry using established methods [16] .
Biochemical analyses
A fasted blood sample was collected into EDTA and reduced glutathione (Sigma -Aldrich) 1mg/ml at the end of the 4-week run-in period and at the end of each 4-week study period for measurement of plasma SPM and F2-isoprostanes. The blood samples were collected on ice, centrifuged immediately and the plasma aliquoted and stored at -80 o C until assay. All samples from each study participant were assayed in the one batch.
SPM included 18-hydroxyeicosapentaenoic acid (18-HEPE), resolvin E1 (RvE1), resolvin E2 (RvE2), resolvin E3 (RvE3) and 18R-resolvin E3 (18R-RvE3), 17-hydroxydocosahexaenoic
resolvin D5 (RvD5), protectin D1 (PD1), maresin-1 (MaR1) and 14-hydroxydocosahexaenoic acid (14-HDHA). SPM were analysed and quantified using liquid chromatography-tandem mass spectrometry (LC-MS/MS) on a Thermo Scientific TSQ Quantum Ultra triple quadrupole LC-MS system (Thermo Scientific) equipped with an electrospray ionization source operated in the negative-ion mode as previously described [17, 18] . The retention time of standards, their mass spectrum, and parent and product ions and collision energy used to identify individual SPMs were as previously reported (see Supplemental Data in reference) [18] . Instrument control and data acquisition were performed with Xcalibur 2.0.7 software.
The limit of detection and limit of quantitation for the precursor's 18-HEPE, 17-HDHA, and 14-HDHA, were 8 and 15 pg/mL, respectively, and for all other SPM, 15 pg/mL and 20 pg/mL, respectively.
Plasma F2-isoprostanes that are markers of lipid peroxidation were measured as by gas chromatography mass spectrometry using methods established in our laboratory [13] .Creactive protein (CRP) was measured using a high-sensitivity monoclonal antibody assay (Dade Behring Marburg GmbH, Marburg, Germany). GT was measured with Roche kit (Roche DiagnosticsGmbH, Mannheim, Germany)
Comparison of plasma SPM in patients with Type 2 diabetes mellitus and healthy volunteers
Plasma SPM in patients with Type 2 diabetes mellitus (n=24) were compared with those of 22 healthy volunteers who were regular drinkers recruited from the general population for a study of similar design that examined the effect of consuming red wine on blood pressure diabetes mellitus were assayed within 6 months. The inter-assay coefficient of variation was 9%.
Statistical analysis
The study of the effects of red wine in patients with Type 2 diabetes mellitus was initially powered to detect changes in the primary outcome of blood pressure [15] . 
RESULTS
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Twenty-four patients with Type 2 diabetes mellitus (19 men and 5 women) were studied and 23 (19 men and 4 women) had plasma SPM measured. The baseline characteristics of the patients are shown in Table 1 At baseline the precursors 18-HEPE, 17-HDHA, the E-series resolvins (RvE1, RvE2, and 18R-RvE3); D-series resolvins (RvD1, 17R-RvD1, RvD2), PD1, MaR1 and 14-HDHA were all detected in plasma. RvE3 and RvD5 were below the limit of quantitation. Drinking RW or DRW did not significantly affect plasma 18-HEPE, the E -series resolvins, 17-HDHA or the D-series resolvins (Table 2) . Similarly, there were no significant effects of drinking RW or DRW on PD1, MaR1 or 14-HDHA (Table 2) . Plasma F2-isoprostanes were 1382 ± 90 pmol/L at baseline, 1194 ± 78 pmol/L after water, 1214 ± 50 pmol/L after DRW and 1305 ± 60 after RW and not significantly different between the treatment periods.
Spearman correlations were used to examine possible relationship between fasting glucose, insulin and hs-CRP and the plasma SPM at baseline and after each intervention. There were no consistent significant correlations observed for any of the plasma SPM with fasting glucose, HbA1c, insulin or hs-CRP in the patients with Type 2 diabetes mellitus.
Comparison of plasma SPM in patients with Type 2 diabetes mellitus and healthy volunteers
The patients with Type 2 diabetes mellitus were on average 5 years older with elevated fasting glucose and triglycerides compared with the healthy volunteers ( Table 1) . Selfreported alcohol consumption was higher in the healthy volunteers (P=0.03) ( Table 1 ). The gender distribution also differed between the two groups with patients with Type 2 diabetes mellitus comprising 19 males and 5 females whereas the healthy volunteers were all men (Table 1) . BMI, blood pressure, total cholesterol, HDL-and LDL-cholesterol and GT were not different between the groups (Table 1) (Figure 1 ). Plasma 14-HDHA was 1218 ± 241 pg/mL in the patients with Type 2 diabetes mellitus compared with healthy volunteers 1847 ± 254 pg/mL (P=0.14). Plasma F2-
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isoprostanes were 1162 ± 51 pmol/L in healthy volunteers and not different to patients with Type 2 diabetes mellitus 1288 ± 66 pmol/L.
DISCUSSION
We have shown for the first time that patients with Type 2 diabetes mellitus have measurable plasma levels of the SPM 18-HEPE, 17-HDHA, E-and D-series resolvins, PD1, MaR1 and 14-HDHA. There is no evidence that the alcohol or polyphenols in red wine affect the levels of these SPM in Type 2 diabetes. Comparison of the baseline levels of plasma SPM with those of healthy volunteers showed that plasma 18-HEPE, 17-HDHA, RvD1 and 17R-RvD1 were all significantly elevated in patients with Type 2 diabetes mellitus. The elevation of plasma SPM in patients with Type 2 diabetes mellitus was coincident with a significant elevation of plasma Hs-CRP compared with healthy volunteers.
The results from this study contrast that of our recent trial in healthy men that showed red wine significantly increased the levels of plasma SPM 18-HEPE, RvD1 and 17R-RvD1 compared with DRW and water [13] . The two studies reported similar effects of red wine on blood pressure, heart rate, GT and HDL-cholesterol with no evident effect of DRW on any of the measured parameters. Possible reasons for the differences between the two studies include the diverse study populations (patients with Type 2 diabetes mellitus compared with healthy volunteers), the lower alcohol intake employed in this trial (24-31g/day in the current study compared with 41g/day in the healthy men) and the possible influence of concurrent antihypertensive and lipid lowering treatment in the patients with Type 2 diabetes mellitus.
There was also no significant effect of consumption of red wine on plasma F2-isoprostanes, this contrasts our results healthy men given red wine and other studies where alcohol was given at a dose ~40g/day. [12, 13, 19, 20] .
Baseline levels of 18-HEPE, 17-HDHA in the patients with Type 2 diabetes mellitus were 2-3 fold higher and the downstream SPM RvD1 and 17R-RvD1were significantly elevated compared with SPM of healthy volunteers. All of these SPM promote inflammation resolution. In animal models of Type 2 diabetes RvD1 has been shown to improve insulin resistance [21] and improve wound healing [22] . The precursors to the E-and D-series resolvins, 18-HEPE and 17-HDHA, are also biologically active. 18-HEPE has been shown to reduce maladaptive cardiac remodelling in mice [23] . 17-HDHA modulates macrophage function, alleviates experimental colitis [24] , and can mediate B-cell differentiation to antibody secreting cells [25] . Possible mechanisms for increased SPM in Type 2 diabetes include increased levels of n-3 fatty acid substrate for SPM synthesis [26] and heightened expression of the enzymes COX-2, that leads to synthesis of 18-HEPE and 17-HDHA [27] and 5-LOX that is involved in synthesis of the E-and D-series resolvins [26] .
Although the two studies were not concurrent the samples from both trials were collected under carefully standardised conditions and stored appropriately for analysis. Furthermore, although the groups were not matched for age and gender, adjusting for these differences in the analysis did not affect the observed differences in plasma SPM. It is possible that use of aspirin and statins, both of which have been shown to increase SPM levels [28, 29] , could explain the higher plasma SPM levels in the patients with Type 2 diabetes mellitus compared with the healthy controls. In our study, 25% of the patients with Type 2 diabetes mellitus reported taking these agents. However, adjusting for use of these medications did not account for baseline differences in plasma SPM between the groups. The patients with Type 2 diabetes mellitus in this study had elevated baseline hsCRP levels compared with healthy volunteers indicative of low grade inflammation. Thus it is possible that the elevated levels of SPMs in patients with Type 2 diabetes mellitus is a homeostatic response to inflammation and that the addition of alcohol was not a sufficient stimulus to further increase plasma SPM levels.
This study has shown that moderate alcohol consumption consumed as red wine does not alter plasma SPM in patients with Type 2 diabetes mellitus. The observation that a number of plasma SPM are elevated in patients with Type 2 diabetes mellitus compared with healthy volunteers needs to be replicated in a larger sample size which can control for major confounders. Values are geometric means and 95% confidence intervals. There were no statistical differences in any of the plasma SPM after intake of red wine compared with DRW or water or after DRW compared with water. 
